The aim of this project is to analyze Epstein-Barr Virus associated antigens, particularly membrane antigens, at the molecular level. They will be identified with new and available monoclonal antibodies. The same antibodies will be used to purify the antigen and isolated material will then be injected into rabbits to generate polypeptide specific anti-sera. The biosynthesis and cellular distribution of the polypeptides will be studied by performing immunoprecipitation on pulse/chase radio-labelled cells and subcellular fractions and by light and electron immunomicroscopy on cells and virions. Finally, the genetic origin of these antigens will be analyzed using in vitro translation techniques, amino acid sequencing of purified antigens and analysis of their expression in translated L cells. The antigens will be studied because they play a central role in all aspects of EBV biology and its interaction with the infected cell and host. Thus, the virion antigens are structural components of the virion, targets for neutralizing antibody and the molecules involved in interactionwith the EBV receptor. Cell surface antigens may play a role both in the maintenance of the transformed state and as targets for immunity. Lastly antigens on EBV producer cells may be involved both in the synthesis of infectious virions and as targets for antibody dependent cellular cytotoxicity. In order to study such antigens a wide variety of expertise in the fields of immunology, biochemistry and molecular biology will be required. The knowledge thus gained should provide insights into the mechanism of infection, cellular transformation, and protective immunity in both normal individuals and in those individuals susceptible to the EBV associated diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031893-05
Application #
3169999
Study Section
Experimental Virology Study Section (EVR)
Project Start
1981-07-01
Project End
1988-11-30
Budget Start
1985-12-01
Budget End
1986-11-30
Support Year
5
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Monk, J Paul; Halabi, Susan; Picus, Joel et al. (2012) Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer 118:4139-47
Ianelli, C J; DeLellis, R; Thorley-Lawson, D A (1998) CD48 binds to heparan sulfate on the surface of epithelial cells. J Biol Chem 273:23367-75
Nicholson, L J; Hopwood, P; Johannessen, I et al. (1997) Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene 15:275-83
Brodeur, S R; Cheng, G; Baltimore, D et al. (1997) Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 272:19777-84
Miyashita, E M; Yang, B; Babcock, G J et al. (1997) Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882-91
Ianelli, C J; Edson, C M; Thorley-Lawson, D A (1997) A ligand for human CD48 on epithelial cells. J Immunol 159:3910-20
Khan, G; Miyashita, E M; Yang, B et al. (1996) Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5:173-9
Decker, L L; Shankar, P; Khan, G et al. (1996) The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med 184:283-8
Thorley-Lawson, D A; Miyashita, E M; Khan, G (1996) Epstein-Barr virus and the B cell: that's all it takes. Trends Microbiol 4:204-8
Sutkowski, N; Palkama, T; Ciurli, C et al. (1996) An Epstein-Barr virus-associated superantigen. J Exp Med 184:971-80

Showing the most recent 10 out of 15 publications